Long-term Restoration of Cardiac Dystrophin Expression in Golden Retriever Muscular Dystrophy Following rAAV6-mediated Exon Skipping by Bish, Lawrence T et al.
original article
580 www.moleculartherapy.org  vol. 20 no. 3, 580–589 mar. 2012 
© The American Society of Gene & Cell Therapy
Although restoration of dystrophin expression via exon 
skipping in both cardiac and skeletal muscle has been 
successfully demonstrated in the mdx mouse, restoration 
of cardiac dystrophin expression in large animal mod-
els of Duchenne muscular dystrophy (DMD) has proven 
to be a challenge. In large animals, investigators have 
focused on using intravenous injection of antisense oligo-
nucleotides (AO) to mediate exon skipping. In this study, 
we sought to optimize restoration of cardiac dystrophin 
expression in the golden retriever muscular dystrophy 
(GRMD) model using percutaneous transendocardial 
delivery of recombinant AAV6 (rAAV6) to deliver a modi-
fied U7 small nuclear RNA (snRNA) carrying antisense 
sequence to target the exon splicing enhancers of exons 
6 and 8 and correct the disrupted reading frame. We 
demonstrate restoration of cardiac dystrophin expres-
sion at 13 months confirmed by reverse transcription-
PCR (RT-PCR) and immunoblot as well as membrane 
localization by immunohistochemistry. This was accom-
panied by improved cardiac function as assessed by car-
diac magnetic resonance imaging (MRI). Percutaneous 
transendocardial delivery of rAAV6 expressing a modified 
U7 exon skipping construct is a safe, effective method 
for restoration of dystrophin expression and improve-
ment of cardiac function in the GRMD canine and may 
be easily translatable to human DMD patients.
Received 24 May 2011; accepted 9 November 2011; published online  
6 December 2011. doi:10.1038/mt.2011.264
IntroductIon
Duchenne muscular dystrophy (DMD) is a lethal, X-linked reces-
sive disease affecting 1 in 3,500 newborn boys that results from a 
mutation in the dystrophin gene.1 Thousands of mutations in the 
79-exon dystrophin gene have been reported with the most severe 
cases being associated with disruption of the reading frame and 
loss of functional dystrophin production.2 Boys typically present 
with symptoms of muscle weakness by age 5, become wheelchair-
bound by early to mid-teens, and die from respiratory failure 
or cardiomyopathy in their late teens to early twenties. Patients 
with dystrophin mutations that maintain the reading frame and 
produce truncated but partially functional dystrophin exhibit 
the milder phenotype of Becker muscular dystrophy (BMD).2 
Unfortunately, no effective therapy or cure exists for DMD, and 
novel therapeutic strategies are in need of development.
One strategy that has potential for treating and possibly cur-
ing DMD in a subset of patients is exon skipping, in which either 
a synthetic or ribo-oligonucleotide antisense sequence, comple-
mentary to specific cis acting signals on the primary RNA tran-
script interferes with splicing of a specific exon or exons. When 
delivered to a cell or animal, these splicing sequences interrupt 
splicing, and induce skipping of the exon or exons in question.3–5 
Effective exon skipping remove the exons causing the frameshift 
mutation responsible for loss of functional dystrophin expres-
sion as well as additional exons as necessary to restore the read-
ing frame. The final result will be restoration of expression of a 
partially truncated but functional dystrophin and amelioration of 
disease phenotype. In other words, exon skipping may convert the 
DMD phenotype to the BMD phenotype or better.
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The sequences that induce exon skipping can be delivered as 
antisense oligonucleotides (AO) or transcribed as an antisense 
sequence linked to U7 or U1 small nuclear RNA (snRNA).5 Proof-
of-concept studies have demonstrated successful exon skipping 
and restoration of dystrophin expression in cells cultured from 
DMD patient muscle biopsies6,7 and canine muscular dystrophy 
muscle biopsies8,9 using the AO approach. In addition, the AO 
approach has been successfully used to restore dystrophin expres-
sion in the mdx mouse model of DMD, although significant car-
diac expression was not initially demonstrated.10,11 More recent 
studies employing AO’s with a morpholino-modified backbone 
have reported highly efficient, systemic restoration of both skel-
etal muscle and cardiac dystrophin in the mdx mouse following 
vascular delivery.12–15 A preclinical investigation of AO-induced 
exon skipping in the Beagle muscular dystrophy model has dem-
onstrated systemic skeletal muscle exon skipping and dystrophin 
expression with improvement in clinical symptoms 22 weeks fol-
lowing vascular delivery, but cardiac dystrophin production was 
modest, and cardiac functional evaluation was not performed.16 A 
second preclinical trial in healthy cynomolgus monkeys reported 
successful skipping of exon 50 in 25% of quadriceps muscle, but 
only 2% of the heart following vascular delivery, underscoring the 
fact that an alternative approach may be necessary for efficient 
cardiac exon skipping in large animals and humans.4 However, 
functional outcomes of exon skipping could not be determined 
in the normal muscles. Currently, the AO approach for single 
exon skipping is being evaluated in clinical trials,3–5 and proof-
of-concept studies have already demonstrated local exon skipping 
and dystrophin expression following direct intramuscular injec-
tion, but efforts directed at cardiac treatment have not yet been 
initiated.17,18
Although the AO approach has been studied extensively and 
is currently being evaluated in clinical trials, it has several limita-
tions, including the need for weekly or biweekly injections and 
lack of demonstration of efficient cardiac exon skipping in large 
animals. In addition, since more than one exon is involved in most 
DMD genetic lesions, multiple AO molecules would be required 
to restore the open reading frame. The need for repeat injections 
can be overcome by using viral-mediated delivery of U7 or U1 
snRNA carrying the antisense sequence to mediate exon skip-
ping. This has been successfully used with lentivirus in human 
DMD myoblasts19,20 and with recombinant adeno-associated virus 
(rAAV) in the mdx mouse.21 Significant skeletal muscle and car-
diac dystrophin expression has been demonstrated in the mdx 
mouse as far as 74 weeks following a single vascular injection of 
rAAV-U7.22,23 However, large animal studies utilizing rAAV-U7 
have not yet been performed, and it is possible that cardiac exon 
skipping following vascular delivery may be as inefficient with 
the rAAV-U7 approach as with the AO approach in beagles16 and 
cynomolgus monkeys.4 Since cardiomyopathy is a leading cause 
of death in DMD patients, this would be a significant therapeutic 
limitation.
Therefore, our goal in this study was to develop a method 
utililzing exon skipping to restore cardiac dystrophin expression 
long-term in a large animal model of DMD. We chose the golden 
retriever model of DMD (GRMD) because it is the largest ani-
mal of DMD available and therefore has a more severe phenotype 
than other smaller canine models of DMD,24 such as the Beagle16 
or Cavalier King Charles Spaniel.9 It harbors a point mutation in 
the 3′ consensus splice acceptor site of intron 6 that causes exclu-
sion of exon 7 and disruption of the reading frame.24 Skipping of 
exons 6 and 8 in this model would, in theory, restore the reading 
frame as well as expression of a partially truncated but functional 
dystrophin. We hypothesized that we could employ percutaneous 
transendocardial delivery of rAAV625,26 expressing a modified U7 
snRNA exon skipping construct (rAAV6-U7-ESE6/8) to achieve 
long-term restoration of cardiac dystrophin expression in GRMD. 
We report successful exon skipping and restoration of cardiac 
dystrophin expression and improved cardiac function in GRMD 




A total of nine GRMD canines were used in this study that was 
designed to evaluate the efficacy of rAAV6-mediated cardiac deliv-
ery of a U7 snRNA modified to skip exons 6 and 8 (U7 targeting 
exon splicing enhancer 6/8, or U7-ESE6/8) and restore the read-
ing frame in the GRMD model. One dog (13 months old, 14 kg) 
was treated with 5 × 1011 gc/kg vector and euthanized 2 months 
postinjection to evaluate dystrophin expression at an early time 
point. The remaining five treated dogs were followed 13 months 
postinjection to assess long-term dystrophin expression. Of these 
five dogs, three were treated with 1.8 × 1012 gc/kg vector (n = 1: 
5 months old, 12 kg; n = 2: 10 months old, 14–17 kg), and two 
were treated with 1.4 × 1013 gc/kg vector (9 months old, 15–19 kg) 
so that a comparison between low- and high-dose vector could 
be made. Three controls were euthanized at 23–25 months of age 
(14–20 kg).
Vector genome detection
Quantitative TaqMan PCR was performed to assess the number 
of vector genome copies delivered to each region of the heart 
in GRMD canines treated with low- and high-dose vector. For 
analysis, the heart was divided into nine regions as depicted in 
Figure 1a. A dose–response relationship was observed. Escalating 
the vector dose by approximately eightfold increased the num-
ber of genomes delivered per cell by at least five to tenfold in all 
regions of the heart (Figure 1b). The lowest gene transfer effi-
ciency was noted in region 1, the anterior base of the heart.
dystrophin mrnA analysis
The exon skipping strategy used to restore dystrophin expression is 
described and depicted in Figure 2. In untreated animals, the mes-
senger RNA (mRNA) lacks exon 7 secondary to the GRMD muta-
tion with subsequent out-of-frame splicing of exon 6 to exon 824  
(Figure 2c,d). Following successful treatment, the mRNA will 
 lack either exons 6–8 or exons 6–9 (removal of exon 9 occurring 
cryptically)27 with splicing of exon 5 to either exon 9 or exon 10, 
both of which are in-frame (Figure 2e). An alternative product 
would be an mRNA lacking either exon 6 or exon 8 in addition to 
exon 7 and/or exon 9, all of which would be out-of-frame. Reverse 
transcription-PCR (RT-PCR) was used to assess exon skipping in 
the cardiac mRNA of GRMD dogs treated with rAAV6-U7-ESE6/8. 
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We designed primers so that the amplified region in the untreated 
hearts would be 953 bp (Δ7), while the amplified region in success-
fully treated areas of the heart would be either 605 bp (Δ6–8) or 
490 bp (Δ6–9).
We detected evidence of successful exon skipping in all treated 
hearts by RT-PCR (Figure 3). When induced exon skipping was 
detected, the predominant band was 490 bp, representing the 
in-frame splicing of exon 5 to exon 10 (Figure 3a–d). This was 
confirmed by sequencing the splice junction (Figure 3e). It should 
be noted, however, that nine regions of each heart were examined 
(Figure 1a), and induced exon skipping was not present in all sam-
ples analyzed. Exon skipping mediated by high-dose rAAV6 was 
more efficient than exon skipping mediated by low-dose rAAV6 
with 5–6 of 9 total samples positive per canine in the high-dose 
group (Figure 3c,d) versus 1–2 out of 9 total samples positive per 
canine in the low-dose group (Figure 3a,b). Quantitative analysis 
confirmed that the ratio of in-frame skipped product to out-of-
frame unskipped product was higher in canines treated with high- 
versus low-dose rAAV6 (Figure 3f).
dystrophin protein analysis
Since we had evidence of in-frame dystrophin mRNA expression 
from our RT-PCR analysis, we next performed immunoblotting 
with an antidystrophin antibody to confirm expression of dys-
trophin protein. The truncated dystrophin expressed in GRMD 
canines is slightly smaller (~409 kDa) than wild-type (427 kDa), as 
expected, due to loss of exons 6–9 (Figure 4a). Dystrophin protein 
was detected in all treated hearts (Figure 4a). However, dystrophin 
protein was expressed at higher levels and in a greater number of 
regions throughout the heart in canines treated with high-dose 
rAAV6 versus low-dose rAAV6 (Figure 4a). In addition, quan-
titative analysis revealed that dystrophin levels in treated GRMD 
canines reached 15–20% of normal (unaffected canine) in most 
regions of the heart following therapy with high-dose rAAV6 
compared to only 3–5% of normal in most regions of the heart 
following injection with low-dose rAAV6 (Figure 4b). As a refer-
ence, dystrophin expression in untreated GRMD canines was ~2% 
of normal (Figure 4b).
We next performed immunohistochemistry (IHC) using an 
antidystrophin antibody to assess tissue distribution and cellu-
lar localization of the truncated dystrophin. Dystrophin staining 
in a normal dog (not affected with GRMD) and in an untreated 
GRMD dog is shown for reference (Figure 5a). We found that 
dystrophin was expressed throughout the hearts of GRMD 
canines treated with rAAV6-U7-E6E8 (Figure 5) and that the 
dystrophin was localized at the cell membranes (Figure 5e). In 
addition, dystrophin expression was greater in canines treated 



























Figure 1 taqman analysis of vector genome distribution in the heart. 
(a) For analysis, biopsies were collected from the LVFW and IVS from base 
to apex as depicted. (b) Biodistribution of vector genomes throughout 
the heart in individual high- and low- dose GRMD canines. Error bars 
represent standard deviations. Ant, anterior; gc, genome copies; GRMD, 
golden retriever muscular dystrophy; IVS, interventricular septum; Lat, 
lateral; LVFW, left ventricular free wall.
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Figure 2 description of exon skipping strategy for restoration of 
dystrophin expression in the GrMd canine. (a) The dystrophin 
gene is large, containing 79 exons. The primary RNA transcript is 
in normal canines is depicted schematically. For simplicity, we have 
focused on the region affected by the GRMD mutation. (b) Splicing 
of the normal primary transcript yields normal mRNA that is trans-
lated into normal dystrophin protein. (c) GRMD is caused by a 
point mutation in dystrophin in the acceptor splice site of intron 6. 
(d) Splicing of this mutant primary transcript yields an mRNA with 
exon 6 fused directly to exon 8. The end result is a nonsense muta-
tion with a premature STOP in exon 8. No functional dystrophin is 
produced from this out-of-frame transcript. (e) Exon skipping is a 
strategy that can be used to restore the open reading frame, and thus 
dystrophin expression, in GRMD. In this study, we used rAAV6 vector 
to express antisense oligonucleotides (AO) to target the exon splic-
ing enhancers (ESE) in exons 6 and 8. By inducing skipping of exons 
6 and 8 in this manner, we were able to restore the open reading 
frame with production of a slightly truncated but functional dystro-
phin. It should be noted that the major product of this exon skip-
ping strategy is an mRNA with exon 5 fused directly to exon 10 (also 
in-frame), as cryptic splicing of exon 9 occurs with high frequen-
cy. The resultant protein contains 75/79 of the original exons. AAV, 
adeno-associated virus; GRMD, golden retriever muscular dystrophy; 
mRNA, messenger RNA; rAAV6, recombinant AAV6.
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with low-dose rAAV6 (Figure 5b,c). The lowest dystrophin 
expression was noted in the anterior base of the heart.
Fibrosis
We assessed cardiac fibrosis by performing IHC for collagen. We also 
co-stained for dystrophin so that a relationship between dystrophin 
expression and fibrosis could be established. In untreated GRMD 
canines, dystrophin expression was absent, and collagen content was 
high (Figure 6). In treated GRMD canines, dystrophin expression 
was restored, and collagen content was reduced (Figure 6). Merging 
of collagen and dystrophin stained images revealed that collagen 
content was reduced specifically in regions where dystrophin expres-
sion was restored (Figure 6). The presence of collagen in a blood ves-
sel wall confirmed specificity of collagen staining (Figure 6).
echocardiography
Echocardiography (echo) was performed on GRMD canines pre- 
and post-treatment and was also performed on age-matched, 
untreated GRMD canines to assess cardiac function and geom-
etry. Data are summarized in Supplementary Table S1. The 
cardiac function and geometry of the animals in this study var-
ied widely and did not correlate well with age or treatment. For 
example, the youngest dog in this study, DM74 (15 months old 
at post-treatment echo), had the most dilated ventricle (left ven-
tricular inner diameter in diastole (LVIDd): 4.4 cm) and most 
depressed contractility (fractional shortening: 15%) despite treat-
ment. In contrast, some of the older dogs in the study, DM109 
and DM110 (23–24 months old at post-treatment echo) had LV 
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Figure 3 rt-Pcr analysis of exon skipping in GrMd canines treated with rAAV6-u7-ese6/8. The GRMD mutation causes loss of exon 7, 
producing an out-of-frame transcript. Treatment with ESE6/8 will cause splicing of exon 5 to exon 9 or exon 10 (as cryptic skipping of exon 9 is a 
well-described phenomenon), both of which are in-frame transcripts. For analysis, biopsies were collected from the LVFW and IVS from base to apex 
as depicted in Figure 1a. Representative gel images are shown from GRMD canines treated with (a,b) 1.8 × 1012 gc/kg of rAAV6-U7-ESE6/8 and 
euthanized 13 months later (n = 3), and (c,d) 1.4 × 1013 gc/kg of rAAV6-U7-ESE6/8 and euthanized 13 months later (n = 2). Samples were considered 
positive for exon skipping if they contained the 490 bp band indicative of in-frame splicing of exon 5 to exon 10, as depicted in the diagram adjacent 
to each gel image. Samples were considered negative for exon skipping if they contained only the 953 bp band representing loss of exon 7 secondary 
to the GRMD mutation. Note that a greater number of samples were positive for exon skipping following treatment with high-dose rAAV6 com-
pared to lower doses of rAAV6. (e) Sequencing of the 490 bp band confirmed splicing of exon 5 to exon 10, which produces an in-frame transcript. 
(f) Quantitative analysis confirmed that the ratio of in-frame skipped product to unskipped product was higher in canines treated with high-versus 
low-dose rAAV6. AAV, adeno-associated virus; GRMD, golden retriever muscular dystrophy; IVS, interventricular septum; LVFW, left ventricular free 
wall; rAAV76, recombinant AAV6; RT-PCR, reverse transcription-PCR.
584 www.moleculartherapy.org  vol. 20 no. 3 mar. 2012 
© The American Society of Gene & Cell Therapy
Restoration of Cardiac Dystrophin in GRMD
shortening: 30–32%) values in the low normal range without 
treatment. As a result of this variability, no significant differences 
in cardiac function and geometry were noted in the treated ani-
mals compared to control.
cardiac MrI
Average peak circumferential strain was greater (P < 0.01) in the 
treated (−12.7 ± 0.5%) versus untreated (−7.2 ± 0.8%) GRMD 
dogs in the lateral LV free wall region of the heart (Figure 7c). 
Other regions showed greater variability among the treated dogs, 
with some dogs demonstrating greater strain than untreated and 
others showing similar values as the untreated dogs. Overall, there 
was general agreement between dystrophin expression and the cir-
cumferential strain measures. For example, expression was lowest 
in GRMD 78 of the treated dogs and this was also the dog that 
showed the lowest average peak circumferential myocardial strain 
of the treated dogs. Furthermore, when GRMD 78 was omitted 
from the comparison between groups due to the low dystrophin 
expression levels in the heart, the average peak circumferential 
strain was greater (P = 0.027) in treated (−12.2 ± 0.8%) versus 




































































Figure 4 Western blot analysis of dystrophin expression in GrMd 
canines treated with rAAV6-u7-ese6/8. For analysis, biopsies were col-
lected from the LVFW and IVS from base to apex as depicted in Figure 1a. 
Normal, untreated unaffected canine (positive control); untreated, 
untreated affected GRMD canine (negative control). (a) Representative 
blots are shown from GRMD canines treated with either 1.8 × 1012 gc/kg 
of rAAV6-U7-ESE6/8 (GRMD 1, GRMD 2) or 1.4 × 1013 gc/kg of rAAV6-U7-
ESE6/8 (GRMD 3, GRMD 4) and euthanized 13 months later. Note that a 
greater number of samples were positive for dystrophin following treatment 
with high-dose rAAV6 compared to low-dose rAAV6. (b) Quantitative, 
densitometric analysis of each western blot was performed. Dystrophin 
expression was higher in GRMD canines treated with high-dose 
rAAV6 (15–20% of normal) versus low-dose rAAV6 (3–5% of normal). 
AAV, adeno-associated virus; Dys, dystrophin; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; GRMD, golden retriever muscular dystro-
phy; IVS, interventricular septum; LVFW, left ventricular free wall; rAAV6, 




















Figure 5 Immunohistochemical (IHc) staining for dystrophin in GrMd 
canines treated with rAAV6-u7-ese6/8. For analysis, sections were 
prepared from the LVFW and IVS from base to apex as depicted in 
Figure 1a. (a) Images from normal (untreated, unaffected) (positive 
control) and untreated (untreated, affected GRMD) (negative control) 
are shown for reference. Representative images are shown from GRMD 
canines treated with (b) 5 × 1011 gc/kg of rAAV6-U7-ESE6/8 and eutha-
nized 2 months later (n = 1), (c) 1.8 × 1012 gc/kg of rAAV6-U7-ESE6/8 
and euthanized 13 months later (n = 3), and (d) 1.4 × 1013 gc/kg of 
rAAV6-U7-ESE6/8 and euthanized 13 months later (n = 2). (e) The inset 
demonstrates membrane localization of dystrophin in an image taken 
at high power (×40 objective). Bar, 200 μm. Note that a greater area of 
myocardium is positive for dystrophin expression following treatment 
with high-dose rAAV6 compared to the lower doses of rAAV6. AAV, ade-
no-associated virus; Ant, anterior; GRMD, golden retriever muscular dys-
trophy; IVS, interventricular septum; Lat, lateral; LVFW, left ventricular 
free wall; rAAV6, recombinant AAV6.




Figure 6 Analysis of fibrosis in GrMd canines treated with rAAV6-
u7-ese6/8. Myocardium was co-stained for dystrophin and collagen I. 
Representative slides are shown from GRMD canines treated with 1.4 × 
1013 gc/kg of rAAV6-U7-ESE6/8 and euthanized 13 months later. An 
untreated GRMD is shown as control. Note that collagen content is high 
when dystrophin staining is low or absent. The white arrow depicts collagen 
staining in a blood vessel wall. Bar, 200 μm. AAV, adeno-associated virus; 
GRMD, golden retriever muscular dystrophy; rAAV6, recombinant AAV6.
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dIscussIon
This is the first report demonstrating long-term restoration of 
cardiac dystrophin expression in a large animal model of DMD. 
rAAV6-U7-ESE6/8 was utilized to skip exons 6 and 8 and restore 
the dystrophin reading frame in GRMD canines. We confirmed 
the presence of exon skipping using RT-PCR and sequencing and 
confirmed expression and membrane localization of dystrophin 
using western blot and IHC in GRMD canines 13 months follow-
ing percutaneous transendocardial delivery of the exon skipping 
vector.
Although efficient and long-term cardiac exon skipping has 
been previously described in the mdx mouse,22,23 there are very few 
reports of cardiac exon skipping in large animal models of DMD. 
For example, weekly to biweekly intravenous injections of AO’s 
were used to induce exon skipping in the Beagle canine X-linked 
muscular dystrophy (CXMD) model.16 Although efficient skeletal 
muscle exon skipping was demonstrated, cardiac exon skipping 
and dystrophin expression was present at only minimal levels. 
Similar results were reported for exon skipping in the cynomolgus 
monkey, with exon skipping product detected in 25% of quadri-
ceps but only 2% of the heart following weekly intravenous injec-
tion of AO’s.4 Since cardiomyopathy is a leading cause of death in 
DMD patients, correction of the skeletal muscle defect without 
the cardiac defect would not be a viable therapeutic option and 
would limit the application of exon skipping as a novel treatment 
for DMD.
The results of these large animal studies suggested to us that 
a specific delivery strategy may be needed to target the heart. We 
have previously demonstrated that percutaneous transendocar-
dial delivery of rAAV6 can be used to achieve efficient cardiac 
transgene expression in the canine.25,26 We therefore developed a 
strategy in this investigation to utilize our minimally invasive car-
diac gene transfer protocol to deliver a rAAV6-U7-snRNA exon 
skipping construct to restore dystrophin expression in the GRMD 
heart. Our novel approach overcomes the two main limitations of 
AO-mediated exon skipping in large animals: lack of significant 
cardiac exon skipping and the need for at least weekly injections 
to maintain continued exon skipping. Indeed, we demonstrated 
cardiac exon skipping and dystrophin expression 13 months fol-
lowing the initial treatment. Such a strategy could be used to com-
plement the already established intravascular delivery method 
for AO-mediated exon skipping that targets skeletal muscle 
efficiently.4,16 Alternatively, an investigator may choose to utilize 
one of the vascular delivery methods currently being employed in 
large animals to target skeletal muscle with delivery of a rAAV-U7 
exon skipping construct so that repeat injections of AO’s would 
not be necessary.28,29 Applied translationally, this strategy would 
allow a DMD patient to undergo percutaneous transendocardial 
rAAV delivery to target the heart and vascular rAAV delivery to 
target the skeletal muscle once in the same treatment session, 
which would offer a definite advantage over strategies requiring 
multiple treatment sessions.
The other leading gene therapy-based approach for dystrophin 
replacement employs rAAV to deliver mini- or micro-dystrophin 
constructs.30,31 This strategy is currently being evaluated in large 
animal models29,30 and human trials.3 In this approach, ~14 kb dys-
trophin complementary DNA (cDNA) is truncated to under 5 kb 
so that it will fit within the packaging capacity of the rAAV vector.30 
The goal is to convert the severe phenotype of DMD to the much 
milder BMD phenotype by inducing expression of a truncated 
but partially functional dystrophin.31 Although this strategy can 
be universally applied to DMD patients, we believe there are cir-
cumstances where exon skipping may provide an advantage over 
gene replacement. For example, the exon skipping product in 
this investigation, Δ6–9, lacks only ~0.5 kb of the 14 kb dystro-
phin cDNA, and it is estimated that a large percentage of DMD 
patients would benefit from the skipping of a similar number of 
exons, most of which are located in the hot spot region of exons 
43–55.3 This skipped product represents >95% of the wild-type 
dystrophin cDNA compared to mini- and micro-dystrophins, 
which represent only ~40% of the cDNA.30 Since restoration of 
dystrophin expression via exon skipping leads to production of a 
protein much closer in size to wild-type dystrophin than the mini- 
or micro-dystrophin approach and since the severity of phenotype 
correlates to some extent with the size of in-frame deletions,2 one 
may expect DMD patients treated with exon skipping to display a 
milder BMD phenotype than those treated with mini- or micro-
dystrophin.
In this study, we evaluated exon skipping mediated by rAAV 
vector using a dose escalation approach. The first dog enrolled 





















































Figure 7 cardiac MrI assessment of function. (a) Left ventricular myo-
cardium in the short-axis view was divided into six equal segments with 
the first segment placed in the anterior region. (b) The slice analyzed was 
located in the mid-papillary region and (c) the average peak circumferen-
tial strain (Ecc) was measured in the treated and untreated GRMD canines. 
(d) Note that both segment 5 and average Ecc are significant if the animal 
with the lowest dystrophin expression is removed from analysis. *P < 0.05. 
Error bars represent standard deviations. GRMD, golden retriever muscular 
dystrophy; MRI, magnetic resonance imaging.
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as this dose of rAAV6-mediated efficient expression of the green 
fluorescent protein (GFP) reporter in the canine heart in our pre-
vious report.25 Surprisingly, this dose of rAAV6-U7-ESE6/8 did 
not mediate significant exon skipping or restoration of dystrophin 
expression. Since that dose was based on data from GFP expres-
sion driven by the chicken β-actin promoter with CMV enhancer 
(CB), we hypothesized that the poor efficiency of exon skipping 
observed at the same dose in this study could be due to either 
(i) reduced activity of the U7 promoter versus the CB promoter 
or (ii) increased complexity involved in achieving successful exon 
skipping and restoration of dystrophin expression versus relative 
ease of inducing GFP expression via traditional transcription and 
translation (iii) or a combination of the two. We are unaware of 
any studies addressing these issues, but we reasoned that increased 
vector dose would lead to increased exon skipping if our hypothe-
sis were true. Therefore, we increased the dose of rAAV6 ~3.5-fold 
(1.8 × 1012 gc/kg), based on vector availability, but only observed a 
modest increase in exon skipping and dystrophin expression.
At this point, we were still concerned that we had not yet 
reached the threshold vector dose to saturate the rAAV6 cellular 
receptors and increase the degree of exon skipping. In order to 
increase the dose of rAAV significantly, we would have to pool 
multiple vector preps per animal based on the yield from the triple 
transfection method of rAAV production, which would impose a 
financial burden. Therefore, in order to dose escalate, we utilized 
high-dose rAAV6 produced using baculovirus expression vectors 
in insect cell culture.32–34 The baculovirus expression vectors sys-
tem is a novel alternative to rAAV vector production using tra-
ditional triple transfection in 293 cells, the method by which the 
rAAV vector used to treat the initial canines in this study was pro-
duced.35 The baculovirus expression vectors system is capable of 
producing vector yields 1–2 logs greater per prep than the tradi-
tional triple transfection method of rAAV production. Therefore, 
we were able to evaluate rAAV6 at a dose of 1.4 × 1013 gc/kg, 
which is approximately eightfold higher than the previous dose 
of rAAV6 used in this study. We found that high-dose rAAV6 was 
superior to low-dose rAAV6 in terms of exon skipping evaluated 
by RT-PCR and dystrophin expression evaluated by both west-
ern blot and IHC. In addition, Taqman analysis confirmed that 
escalating the vector dose by approximately eightfold increased 
the number of genomes delivered per cell by at least five to ten-
fold in all regions of the heart. Future investigation will be needed 
to determine if further dose escalation will result in increased 
vector genome delivery and exon skipping since it is unclear if 
our high dose was sufficient to saturate cellular rAAV6 receptors 
and/or intracellular exon skipping machinery.
It should also be noted that the lowest gene transfer, both in 
terms of vector genome content and restoration of dystrophin 
expression, was observed in the anterior base of the heart. This 
was a result of the technical difficulty associated with accessing 
this region of the heart following advancement of the injection 
catheter into the LV retrograde via the aorta. Future effort will be 
directed towards identifying a strategy to increase gene transfer 
to this region.
We analyzed cardiac function at 13 months by both echocar-
diography and magnetic resonance imaging (MRI). We did not 
detect a significant improvement in cardiac function in treated 
GRMD canines compared to untreated controls via echocardiog-
raphy. It is probable that the inherent variability in GRMD cardio-
myopathy makes it difficult to detect significant changes in cardiac 
function via echocardiography. For example, two recent studies 
were unable to detect evidence of LV dilation and dysfunction by 
standard echocardiography in a total of 21 GRMD canines aged 
6 months to 2 years, which spans the age–range of the dogs in 
our study.36,37 A historical study reported LV dysfunction in 1/7 
GRMD canines by 1 year of age,38 while another report describes 
hyperechoic LV lesions on echocardiography in 12/13 GRMD 
canines.39 Finally, a preliminary study with n = 1 at 6 months and 
1 year reported depressed fractional shortening compared to n = 1 
control at 6 months and 1 year.40 Indeed, as demonstrated in 
Supplementary Table S1, cardiac function and geometry, did not 
correlate with treatment or age in the dogs in our study.
However, using cardiac MRI, we were able to detect increased 
LV circumferential strain in the lateral free wall segment indicat-
ing improved regional cardiac function. In addition, if the dog 
with lowest dystrophin expression was removed, the average peak 
circumferential strain was greater in treated versus untreated 
GRMD dogs. Cardiac MRI is more sensitive than echocardiog-
raphy in analyzing cardiac function, especially in DMD. Both 
Hor41 and Ashford42 demonstrated that MRI strain analysis can 
be used to detect progressive occult cardiovascular dysfunction 
in DMD patients with normal global function, and previous stud-
ies have shown a reduction of circumferential cardiac strain with 
disease progression in mdx mice43 and children with DMD.44 
Furthermore, tagged imaging with circumferential strain analysis 
has been shown to be a sensitive measure to monitor improvement 
following transendocardial gene transfer of vascular endothelial 
growth factor (VEGF) in a canine model of ischemic cardiomy-
opathy.45 Similarly, the rAAV-mediated exon skipping strategy 
implemented in this study seems to be effective in ameliorating 
the degree of cardiac dysfunction as determined by MRI measure-
ments of circumferential strain.
Although we report promising preclinical data describing the 
use of rAAV6-mediated exon skipping to restore cardiac dystro-
phin expression in GRMD, there are several considerations which 
must be discussed and/or addressed before clinical translation to 
DMD patients. Safety is a critical issue, and although the proce-
dure was well tolerated in canines for the 13-month duration of 
this study, it is unclear if any long-term toxicity will result from 
either the procedure itself or from chronic expression of anti-
sense RNA. For example, cardiac fibrosis resulting from the mul-
tiple injections required for global cardiac gene transfer could 
lead to arrhythmogenesis later in life, and long-term, constitu-
tive expression of antisense RNA could lead to disruption of off- 
target, endogenous gene expression. In addition, any complication 
associated with cardiac catheterization, including periprocedural 
bleeding and infection, could occur each time the protocol is uti-
lized. It should also be noted that while the canines used in the 
study may closely approximate the size of newly diagnosed DMD 
patients, further scaling up of vector doses may be necessary due 
to interspecies variation in gene transfer efficiency and may also 
be necessary to achieve improvement in cardiac function.
In summary, this is the first report demonstrating long-term 
restoration of cardiac dystrophin expression in a large animal 
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model of DMD. We employed percutaneous transendocardial 
delivery of rAAV6-U7-ESE6/8 to induce exon skipping and dem-
onstrated evidence of successful exon skipping and dystrophin 
expression 13 months following treatment. We also demonstrated 
reduced fibrosis and improved cardiac function via cardiac MRI 
in treated animals. Further investigation will be directed towards 
treating GRMD canines at an earlier age and/or increasing vector 
dose so that increased exon skipping and additional improvement 
in cardiac function may be appreciated.
MAterIAls And MetHods
Vector design and production. Each vector was designed to express 
modified U7 snRNA (U7SmOPT)21 carrying antisense sequence to 
target the canine exon splicing enhancers of exons 6 and 8 (ESE6/8) 
under control of the U7 promoter. The optimal antisense sequences 
were determined previously by in vitro screening in GRMD myotubes 
with subsequent confirmation of function in GRMD skeletal muscle 
(Published abstract: Vulin, A et al. (2006). Neuromuscul Disord 16: 
722–723. doi:10.1016/j.nmd.2006.05.249). rAAV6 vector used for the 
low-dose treatment group was produced using the previously described 
pseudotyping protocol by the Vector Core of the Children’s Hospital of 
Philadelphia.35 Briefly, rAAV genomes containing rAAV2 inverted ter-
minal repeats were packaged by triple transfection of 293 cells with a 
cis-plasmid containing the U7-ESE6/8 exon skipping construct, an ade-
novirus helper plasmid, and a chimeric trans-helper plasmid containing 
the rAAV2 rep gene fused to the capsid gene of rAAV6. rAAV6 vector 
used for the high-dose treatment group was produced using the BEV 
system in insect cell culture.32–34
U7 Promoter: 5′CACATACGCGTTTCCTAGGAAACCAGAGAA 
GATCAAAGCCCCTCTCACACACCGGGGAGCGGGGAAGAGAA 
CTGT T T TGCT T TCAT TGTAGACCAGTGAAAT TGAGGGG 
TTTTCCGACCGAAGTCAGAAAACCTG 3′
U7SmOPT: 5′ CTCCAAAAATT 3′
ESE 6: 5′ CTGGGTCCGACAATCAACTCGTAATTATCCACAGG 
TTAATGT 3′
ESE 8: 5′ TGTATATCACATCACTCTTCCAAGTTTTGCCTCAAC 
AAGT 3′
Animal use and vector delivery protocol. All animals were handled in 
compliance with National Institute of Health and institutional guidelines 
that were approved by the Institutional Animal Care and Use Committee 
of the University of Pennsylvania. Nine affected GRMD canines were used 
in this study. One dog (13 months old, 14 kg) was treated with 5 × 1011 gc/kg 
vector and euthanized 2 months postinjection to evaluate dystrophin 
expression at an early time point. The remaining five treated dogs 
were followed 13 months postinjection to assess long-term dystrophin 
expression. Of these five dogs, three were treated with 1.8 × 1012 gc/kg 
vector (n = 1: 5 months old, 12 kg; n = 2: 10 months old, 14–17 kg), and 
two were treated with 1.4 × 1013 gc/kg vector (9 months old, 15–19 kg) 
so that a comparison between low- and high-dose vector could be 
made. Three untreated controls were euthanized at 23–25 months of 
age (14–20 kg).
The vector delivery procedure was performed under general anes-
thesia, and dogs were placed in left lateral recumbency. Heart rate, 
respiratory rate, systolic blood pressure, electrocardiogram, and oxygen 
saturation were monitored throughout the anesthetic period. A right 
carotid arterotomy was performed, and a 7 French introducer was placed 
in the vessel, followed by insertion of the injection catheter. This catheter 
was a steerable injection catheter with an adjustable length core needle 
(MyoCath; Bioheart, Sunrise, FL), which has previously been employed to 
deliver rAAV vector in our laboratory.25,26 The catheter was flushed with 
heparinized blood before vector infusion to prevent inactivation of the 
virus.46 Next, under fluoroscopic guidance, the catheter was advanced 
into the LV cavity, and by steering the needle tip and adjusting the needle 
length, ~60 transendocardial injections of 250 μl each were performed to 
target the LV free wall and interventricular septum from base to apex and 
from endocardium to epicardium with rAAV vector. Contrast media was 
added to the vector solution so that injection sites could be visualized. 
This allowed us to differentiate between injected and uninjected regions 
of the heart and helped to ensure that the vector solution was distributed 
globally throughout the myocardium.
For each procedure vector was mixed with 2 cc of sterile contrast 
solution (Omnipaque; Nycomed Imaging, Oslo, Norway) and diluted 
with sterile saline to produce 15 cc for injection. Lidocaine (2 mg/kg as a 
bolus followed by a constant rate infusion at 50 μg/kg/min) was initiated 
if ventricular tachycardia developed during the procedure. After recovery, 
dogs were treated with carprofen for 2 days and amoxicillin–clauvolonic 
acid for 5 days.
TaqMan PCR. To determine the number of vector genome copies delivered 
per cell, samples were snap-frozen in liquid nitrogen at the time of eutha-
nasia. Following DNA extraction, genome copy (gc) titres were quantified 
by TaqMan PCR (Applied Biosystems, Foster City, CA) using primers and 
probes designed against the exon skipping construct. The amplicon was 64 
base pairs. 1 μg of template DNA was used per reaction, and several controls 
were performed to confirm the specificity and accuracy of the PCR. A spike 
control was performed in which the test sample was spiked with exogenous 
test assay target to rule out PCR inhibition. The assay was also performed 
on samples from the negative control, saline-injected animal to determine 
background signal of the assay, which was negligible (<1 gc per 5,000 cells, 
or >1 log lower than the minimum gc detected in experimental samples).
Forward primer: CCTGCTCCAAAAATTTGTATATCAC
Reverse primer: CTTCCGCAAACTTGTTGAG
Probe: 6FAM-TCA CTC TTC CAA GTT TTG-MGBNFQ
RT-PCR and DNA sequencing. At the time of euthanasia, cardiac biopsies 
were collected as depicted in Figure 1 and snap-frozen in liquid nitrogen. 
Tissue was crushed with a mortar and pestle on dry ice, and total RNA was 
isolated using the TRIzol extraction method (Invitrogen, Carlsbad, CA). 
One hundred fifty nanograms of RNA from each sample was subjected 
to single-strand reverse transcription and 5μl of the generated cDNA was 
used as the template in the subsequent nested PCR reactions to detect evi-
dence of exon skipping (Gene Amp RNA PCR Core Kit, Roche Applied 
Biosystems, Branchburg, NJ). The dystrophin primers used for the nested 
PCRs were designed to amplify exons 1–10. DNA sequencing to confirm 
splicing of exon 5 to exon 10 was performed by the DNA sequencing core 
of the Children’s Hospital of Philadelphia.
Reaction 1
(i) Exon 1: 5′ CAT CAG AGA AAA ACG AAT AGG 3′
(ii)  Exon 10: 5′ AAT CTC TCC TTG GGC TTG CAG 3′
Reaction 2
(i) Exon 1: 5′ GTG GGA AGA AGT AGA GGA CTG 3′
(ii)  Exon 10: 5′ CTC AGC TGA AAG AAG CCA CGA 3′
Immunoblot. Cardiac biopsies were obtained for western blotting as 
depicted in Figure 1 and snap-frozen in liquid nitrogen. Specimens were 
pulverized, homogenized in 10 volumes of triple-detergent lysis buffer 
(50 mmol/l Tris, pH 8.0, 0.1% SDS, 1.0% Triton X-100, 0.5% DOC, 5 mmol/l 
EDTA, 50 m,ol/l DTT, 0.4 tablet/10 ml Complete Protease Inhibitor Cocktail 
Tablets (Roche, Indianapolis, IN)), and centrifuged at 13,000 rpm for 5 
minutes. Protein concentration of the supernatant was then determined 
using the BioRad Protein Assay (Bio-Rad Laboratories, Hercules, CA), and 
a 50 μg aliquot of each sample was denatured using an equal volume of 2× 
sample loading buffer (130 mmol/l Tris, pH = 8.0, 20% glycerol, 4.6% SDS, 
2% DTT, 0.02% bromophenol blue) at 100 °C (5 minutes) then fractionated 
electrophoretically on a 2% SDS-polyacrylamide gel (Lonza, Rockland, ME). 
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Proteins were then electroblotted onto a polyvinylidene fluoride mem-
brane (Immobilon-P; Millipore, Bedford, MA) using the iBlot transfer 
apparatus (Invitrogen) after a 30 minute incubation in NuPAGE transfer 
buffer with 10% methanol (Invitrogen). The membrane was subsequently 
blocked by incubating in Tris-buffered saline containing 5% nonfat dry 
milk and 0.05% Tween 20. Immunoblotting was performed to detect dys-
trophin using a rabbit polyclonal antibody raised against a C-terminal 
epitope (1:2,000; Abcam, Cambridge, MA). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (1:4,000; Santa Cruz Biotechnology, Santa 
Cruz, CA) was used as a loading control. Secondary antibody (anti-
rabbit; GE Healthcare, Buckinghamshire, UK) was used at a dilution 
of 1:2,000. Detection was performed using the Super Signal West Pico 
Chemiluminescent Substrate kit (Pierce, Rockford, IL).
IHC. At the time of euthanasia, tissues were harvested for evaluation of 
dystrophin expression. The heart was divided into sections as depicted in 
Figure 1; each section was frozen in OCT embedding compound (Tissue 
Tek, Torrance, CA), and 10 μm cryosections were prepared. Sections were 
blocked in 5% bovine serum albumin (BSA)/phosphate-buffered saline 
(PBS) and subsequently incubated overnight at 4 °C in 5% BSA/PBS con-
taining a rabbit polyclonal antibody raised against a C-terminal epitope 
of dystrophin (1:2,000; Abcam) or collagen I (1:100; Abcam). Following 
washes in PBS, sections were incubated in 5% BSA/PBS containing Alexa 
Fluor IgG secondary antibody (1:2,000; Invitrogen) for 1 hour in the dark 
at room temperature. Slides were then mounted with Vectashield DAPI 
media (Vector Laboratories, Burlingame, CA) and examined for fluores-
cence using a Leitz DMRBE fluorescent microscope (Leica, Bannockburn, 
IL) equipped with a Micro Max digital camera (Princeton Instruments, 
Trenton, NJ) interfaced with Image Pro Plus software (Media Cybernetics, 
Bethesda, MD). Exposure times were equal for all samples. The threshold 
for detection was set above background levels measured in the untreated 
canine specimens.
Echocardiography. Echocardiography was performed on the treated dogs 
before gene delivery and again before euthanasia and on three untreated, 
affected dogs using a Philips Sonos 7500 (Philips, Wilmington, MA) and a 
2–4 MHz transducer. The same sonographer performed all studies, which 
included 2D, M-mode, spectral doppler, and tissue doppler of the lateral 
mitral valve annulus.
Cardiac MRI. Anesthesia was induced in dogs with an intravenous infu-
sion of propofol (1.0–2.0 mg/min/kg) and fentanyl (0.005 mg/kg/min) via 
the cephalic vein, and maintained using reduced concentrations (propo-
fol: 0.2 mg/kg/min; fentanyl: 0.7 mcg/kg/min). MR data were acquired 
in apnea by turning off the ventilator, along with infusion of a bolus of 
cisatracurium (0.1 mg/kg). Respiration, electrocardiogram, O2 saturation, 
and blood pressure were monitored during the MR scanning protocol.
For image acquisition, dogs were placed in the dorsal position in the 
bore of the magnet of a GE 1.5 Telsa Signa MR system (GE Healthcare, 
Milwaukee, WI). A torso array receive-only coil was positioned over 
the thoracic region. Cardiac imaging was performed with retrospective 
electrocardiogram gating. Cardiac-gated tagged images were acquired 
using a fast spoiled gradient recalled sequence (field of view 24 × 24 cm; 
acquisition matrix 256 × 128; repetition time 9.2 ms; echo time 5.5 ms; flip 
angle 20°). Grid tag spacing was 7 mm. Images were acquired in the short-
axis trans-ventricular view (4–5 slices, 8 mm slice thickness, no slice gap). 
Positioning of the short-axis images was achieved using sagittal localizers 
and long-axis four-chamber images of the heart.47 Triggering utilized a 
single cardiac phase cycle with minimum trigger delay and 16 frames per 
cardiac cycle.
Analysis of the tagged images was performed using harmonic phase 
analysis (HARP; Diagnosoft, Palo Alto, CA) for peak circumferential 
myocardial strain.44,48 The short-axis slice in the mid-papillary region 
of the left ventricle was chosen for analysis. In a middle-frame image, 
epicardial and endocardial traces were drawn and then automatically 
propagated to create a mesh dividing the myocardium into six regions 
in the short-axis view of all 16 frames acquired in the cardiac cycle. For 
consistency, the first segment was placed starting at the anterior region 
of the ventricular septum. The average peak circumferential myocardial 
strain from each segment was calculated for the mid-wall using Eulerian 
strain algorithms.49
suPPleMentArY MAterIAl
Table S1. Echocardiography data from GRMD canines pre- and post-
treatment with AAV6-U7-ESE6/8.
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